Controversies in adjuvant endocrine therapy for pre- and post-menopausal women with breast cancer

European Journal of Cancer, Supplement

Volumn 6, Issue 14, 2008, Pages 4-9

  Ciccarese, Mariangela ^a   Lorusso, Vito ^a   De Laurentis, Michele ^b  

^a VITO FAZZI HOSPITAL   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Aromatase inhibitors; Early breast cancer; Oestrogen receptors; Pgr negative; Tamoxifen; Toxicity profile

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; LUTEINIZING HORMONE; PLACEBO; TAMOXIFEN;

ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL TRIAL; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GYNECOLOGIC DISEASE; HORMONAL THERAPY; HOT FLUSH; HUMAN; MONOTHERAPY; MOOD DISORDER; MYALGIA; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION;

EID: 55649092634     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2008.06.016     Document Type: Article

References (43)

1. Goldhirsch A., Wood W.C., Gelber R.D., et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21 (2003) 3357-3365
2. The ATAC Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 (2008) 45-53
3. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
4. Coombes R.C., Hall E., gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
5. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
6. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
7. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23 (2005) 5138-5147
8. Boccardo F., Rubagotti A., Guglielmini P., et al. Switching to anastrozole versus continued tamoxifen treatment for early breast cancer: updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17 (2006) vii10-vii14
9. Kaufmann M., Jonat W., Hilfrich J., et al. Inproved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 25 (2007) 2664-2670
10. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med 349 (2003) 1793-1802
11. Mamounas E., Jeong J.H., Wickerham D.L., et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention to treat analysis of the national surgical adjuvant breast and bowel project B-33 trial. J Clin Oncol 26 (2008) 1965-1971
12. Jakesz R., Samonigg H., Greil R., et al. Extended adjuvant treatment with anastrozole: results from the ABCSG trial 6a. J Clin Oncol 23 (2005) 10s
13. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor positive breast cancer: updated findings from NCIC CTG MA17. J Natl Cancer Inst 97 (2005) 1262-1271
14. Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 57 (1988) 608-611
15. Fisher B., Costantino J., Redmond C., et al. A randomized controlled trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumours. N Engl J Med 320 (1989) 479-484
16. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen for lymphonode negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93 (2001) 684-690
17. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival. An overview of the randomised trials. Lancet 365 (2005) 1687-1717
18. Tormey D.C., Gray R., and Falkson H.C. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymphonode positive breast cancer: Eastern Cooperative Oncology Group. J Natl Cancer Inst 88 (1996) 1828-1833
19. Peto R, Davies C on behalf of the ATLAS Collaboration. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11500 women: preliminary results. SABCS; 2007.
20. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with Lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006;24:1332-41.
21. Thürlimann B., Price K.N., Gelber R.D., et al. Is chemotherapy necessary for premenopausal women with lower risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat (2008) 9912-9919
22. Albain K, Barlow W, O'Malley F, et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node positive, estrogen (ER) and/or progesterone (Pgr) receptor positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). In: 27th annual San Antonio breast cancer symposium, San Antonio, TX; 2004 (abstract 37).
23. Viale G., Regan M., Maiorano E., et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal women with early breast cancer. Results from study BIG 1-98. J Clin Oncol 25 (2007) 3846-3852
24. Dowsett M., Allred C., Knox J., et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (Her-2) status with recurrence in the arimidex tamoxifen, alone or in combination trial. J Clin Oncol 26 (2008) 1-8
25. Riggins R.B., Schrecengost R.S., Guerrero M.S., et al. Pathways to tamoxifen resistance. Cancer Lett 256 (2007) 1-24
26. Cuzick J., Ambroisine L., Davidson N., et al. Use of luteinising hormone releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone receptor positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369 (2007) 1711-1723
27. Bines J., Oleske D.M., and Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14 (1996) 1718-1729
28. Petrek J.A., Naughton M.J., Case L.D., et al. Incidence, time course and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24 (2006) 1045-1051
29. Jonat W., Kaufmann M., Sauerbrei W., et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node positive breast cancer. The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20 (2002) 4628-4635
30. Kaufmann M., Jonat W., Blamey R., et al. Survival analyses from the ZEBRA study: goserelin (Zoladex) versus CMF in premenopausal women with node positive breast cancer. Eur J Cancer 39 (2003) 1711-1717
31. Castiglione-Gertsch M., O'Neill A., Price K.N., et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymphnode negative breast cancer: a randomized trial. J Natl Cancer Inst 95 (2003) 1833-1846
32. Kaufmann M., Graf E., Jonat W., et al. J Clin Oncol 23 (2005) 7842-7848
33. Smith I.E., and Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 348 (2003) 2431-2442
34. Mitwally M.F., and Casper R.F. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 75 (2001) 305-309
35. Smith I., Dowsett M., Yap Y.S., et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 24 (2006) 2444-2447
36. Price K.N., and Goldhrisch A. Clinical trial update: International Breast Cancer Study Group. Breast Cancer Res 7 (2005) 252-254
37. Brown R.J., and Davidson N.E. Adjuvant hormonal therapy for premenopausal women with breast cancer. Semin Oncol 33 (2006) 657-663
38. Francis P., Fleming G., Nasi M.L., et al. Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or Pgr+) breast cancer: the SOFT, TEXT, and PERCHE trials. Breast 12 (2003) S44
39. Osborne C.K., Coronado E.B., and Robinson J.P. Human breast cancer in the athymic nude mouse: cytostatic effects of long term antiestrogen therapy. Eur J Cancer Clin Oncol 23 (1987) 1189-1196
40. Gottardis M.M., and Jordan V.C. Development of tamoxifen stimulated growth of MCF-7 tumors in athymic mice after long term antiestrogen administration. Cancer Res 48 (1988) 5183-5187
41. Jonat W., Gnant M., boccardo F., et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone sensitive early stage breast cancer: a meta-analysis. Lancet Oncol 7 (2006) 991-996
42. Punglia R.S., Kuntz K.M., Winer E.P., et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early stage breast cancer: a decision analysis. J Clin Oncol 23 (2005) 5178-5187
43. Cuzick J., Sasieni P., and Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. Br J Cancer 94 (2006) 460-464